Avidity Biosciences, Inc. (RNA)
| Market Cap | 666.88M |
| Revenue (ttm) | 9.62M |
| Net Income (ttm) | -95.75M |
| Shares Out | 46.90M |
| EPS (ttm) | -2.46 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 322,154 |
| Open | 14.49 |
| Previous Close | 14.70 |
| Day's Range | 14.10 - 15.44 |
| 52-Week Range | 14.10 - 29.59 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 49.80 (+250.2%) |
| Earnings Date | n/a |
About RNA
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; and to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable...
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for RNA stock is "Strong Buy." The 12-month stock price forecast is 49.80, which is an increase of 250.21% from the latest price.
News
Avidity Biosciences Highlights FSHD Program at Virtual Investor and Analyst Event
LA JOLLA, Calif., Dec. 9, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotid...
Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Tops Revenue Estimates
Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of -7.94% and 44.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the st...
Avidity Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights
LA JOLLA, Calif., Nov. 9, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotid...
Earnings Preview: Avidity Biosciences, Inc. (RNA) Q3 Earnings Expected to Decline
Avidity Biosciences, Inc. (RNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Avidity Biosciences to Participate in Upcoming Investor Conferences
LA JOLLA, Calif., Nov. 2, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA) a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide...
Avidity Biosciences Announces Changes to its Board of Directors
LA JOLLA, Calif., Aug. 25, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA) a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotid...
Avidity Biosciences Enters Into Collaboration with FSHD Clinical Trial Network to Support Development of Biomarkers f...
LA JOLLA, Calif., Aug. 16, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleoti...
Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Tops Revenue Estimates
Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of 9.09% and 73.80%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Avidity Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights
LA JOLLA, Calif., Aug. 9, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotid...
Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock
LA JOLLA, Calif., Aug. 3, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotid...
Will Avidity Biosciences, Inc. (RNA) Report Negative Q2 Earnings? What You Should Know
Avidity Biosciences, Inc. (RNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock
LA JOLLA, Calif., Aug. 2, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotid...
Avidity Biosciences Shares Gain As Its Oligonucleotide Candidate Enters Early-Stage Trial In Muscle Wasting Disorder
The FDA has signed off Avidity Biosciences Inc's (NASDAQ: RNA) Phase 1/2 MARINA trial of AOC 1001 in adults with myotonic dystrophy type 1 (DM1). Myotonic dystrophy is characterized by progressive muscl...
Avidity Biosciences Announces Updates on the Pipeline and Platform at Virtual Investor and Analyst Event
LA JOLLA, Calif., May 19, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleot...
Avidity Biosciences Reports First Quarter 2021 Financial Results and Recent Highlights
LA JOLLA, Calif., May 12, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleot...
Avidity Biosciences to Host Virtual Investor and Analyst Event on May 19, 2021
LA JOLLA, Calif., May 3, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleoti...
Avidity Biosciences Reports Fourth Quarter and Year-End 2020 Financial Results and Recent Highlights
LA JOLLA, Calif., March 15, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucle...
Avidity Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
LA JOLLA, Calif., Dec. 22, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleo...
Avidity Biosciences Announces Addition to the Nasdaq Biotechnology Index
LA JOLLA, Calif., Dec. 21, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleo...
Avidity Biosciences Reports Third Quarter 2020 Financial Results and Recent Highlights
LA JOLLA, Calif., Nov. 10, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleo...
Avidity Biosciences to Present at the Virtual Chardan 4th Annual Genetic Medicines Conference 2020
LA JOLLA, Calif., Sept. 28, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucle...
Avidity Biosciences Enters into Collaboration to Study the Natural History of Myotonic Dystrophy Type 1
SAN DIEGO, Sept. 8, 2020 /PRNewswire/ -- Avidity Biosciences, Inc.
Avidity Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights
SAN DIEGO, Aug. 10, 2020 /PRNewswire/ -- Avidity Biosciences, Inc.
Avidity Biosciences Appoints Jae Kim, M.D. as Chief Medical Officer
SAN DIEGO, July 27, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Co...